<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296006</url>
  </required_header>
  <id_info>
    <org_study_id>BED(In)(41)</org_study_id>
    <nct_id>NCT04296006</nct_id>
  </id_info>
  <brief_title>Neurobehavioral Mechanisms of Cocaine Choice</brief_title>
  <official_title>Neurobehavioral Mechanisms of Cocaine Choice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua A. Lile, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this protocol is to use a drug-vs-money choice task, reinforcement learning
      modeling and fMRI to determine the neurobehavioral and neurobiological decision-making
      &quot;profile&quot; associated with the decision to take cocaine and the reduced cocaine choice that
      occurs during behavioral and pharmacological interventions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A placebo-controlled, randomized, within-subjects design will be used to assess drug-vs-money choice in cocaine use disordered subjects as a function of alternative reinforcer value and d-amphetamine SR treatment.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>d-Amphetamine doses will be administered under double-blind conditions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative</measure>
    <time_frame>Choices occur across a 40 minute session</time_frame>
    <description>The reinforcing effects of cocaine are determined using a reinforcement learning choice task. Subjects complete trials in which they could possibly receive the available cocaine dose or money. Reinforcing effects are measured for a fixed cocaine dose during both d-amphetamine and placebo maintenance and when three amounts of money are available as alternatives to cocaine.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Cocaine Use Disorder</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine choice during d-amphetamine maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine choice during placebo maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained Release d-amphetamine</intervention_name>
    <description>Twice daily administration of active or placebo d-amphetamine</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <other_name>Dexedrine Spansule SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Money</intervention_name>
    <description>Three money values offered as alternatives to cocaine</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent cocaine use, otherwise healthy

        Exclusion Criteria:

          -  Laboratory results outside of clinically acceptable ranges, history of or current
             serious physical or psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratory of Human Behavioral Pharmacology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Joshua A. Lile, Ph.D.</investigator_full_name>
    <investigator_title>Professor of Behavioral Science</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

